Stoke Therapeutics
3 Preston Court
Suite 102
Bedford
Massachusetts
01730
United States
Tel: 781-430-8200
Website: https://www.stoketherapeutics.com/
Email: info@stoketherapeutics.com
About Stoke Therapeutics
Stoke Therapeutics is a biotechnology company working to increase gene expression to treat a wide array of severe genetic diseases, including genetic conditions affecting the central nervous system, eye, and liver. Stoke was launched in 2018 with a $40 million Series A investment funded by Apple Tree Partners.
YEAR FOUNDED:
2018
LEADERSHIP:
Founder, CBO and COO: Huw M. Nash, Ph.D.
CEO: Edward M. Kaye, M.D.
CMO: Barry Ticho, M.D., Ph.D., FACC
Co-Founder & VP, Head of Biology: Isabel Aznarez, Ph.D
VP, Head of Chemistry: Charles R. Allerson, Ph.D.
PIPELINE:
Please click here for Stoke Therapeutics' pipeline
CAREER:
Please click here for Stoke Therapeutics' job opportunities.
94 articles with Stoke Therapeutics
-
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
3/15/2023
Stoke Therapeutics, Inc. today announced that the FDA will allow the administration of a higher single dose of STK-001 (70mg) in its ongoing Phase 1/2a MONARCH study of children and adolescents with Dravet syndrome.
-
Stoke Therapeutics to Participate at Upcoming March 2023 Investor Conferences
2/27/2023
Stoke Therapeutics, Inc. announced that management will be participating at the following upcoming investor conferences.
-
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
2/7/2023
Stoke Therapeutics, Inc. today announced that management will present at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 4:20 p.m. ET.
-
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
1/9/2023
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today outlined its expected milestones and the following strategic priorities for 2023.
-
Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Stoke Therapeutics, Inc. today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 2:15 p.m. ET (11:15 a.m. PT).
-
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting
12/2/2022
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations related to the ongoing clinical development of STK-001, the first potential new medicine to treat the underlying cause of Dravet syndrome.
-
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting
11/29/2022
Seven abstracts related to the Company’s work in Dravet syndrome will be presented, including data from a combined interim analysis of the Phase 1/2a MONARCH and ADMIRAL studies of STK-001.
-
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates - November 14, 2022
11/14/2022
Stoke Therapeutics, Inc. today reported financial results for the third quarter of 2022 and provided business updates, including positive data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome.
-
Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome
11/10/2022
Stoke Therapeutics, Inc. today announced that management will hold a webinar and conference call for analysts and investors at 8:30 a.m. Eastern Time on Monday, November 14, 2022.
-
Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)
8/25/2022
Stoke Therapeutics today announced enrollment of the first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA).
-
BioSpace spoke with industry executives and investors about the current economic situation in the biotech industry and sourced tips on how leaders can weather the downturn.
-
Stoke Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
8/8/2022
Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, reported financial results for the second quarter of 2022 and provided business updates.
-
Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference
6/1/2022
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4:00 p.m. ET.
-
Stoke Therapeutics Reported First Quarter Financial Results and Provides Business Updates
5/10/2022
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2022 and provided business updates.
-
Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002
5/2/2022
Stoke Therapeutics, Inc. (Nasdaq: STOK), today announced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002.
-
Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
4/7/2022
Stoke Therapeutics, Inc. announced today the upcoming presentation of new preclinical data on STK-002 at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting being held May 1-4, 2022 in Denver, Colorado.
-
Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
4/5/2022
Stoke Therapeutics, Inc. today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 8:00 a.m. ET.
-
Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
3/10/2022
Stoke Therapeutics, Inc. today reported financial results for the full year ended December 31, 2021 and provided business updates.
-
Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference
2/28/2022
Stoke Therapeutics, Inc. announced that management will participate on the Orphan Neuro Panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.
-
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
1/10/2022
Acadia Pharmaceuticals and Stoke Therapeutics, Inc. announced today that the companies have entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS).